Skip to content

BioLife Solutions BLFS Preferred Stock, Par or Stated Value Per Share

Preferred Stock, Par or Stated Value Per Share at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Azenta logo
AzentaAZTA
Revvity logo
RevvityRVTY
Artivion logo
ArtivionAORT
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.25B+33.1%
Enterprise value$1.24B+38.1%
P/S12.5×+0.5×

Profitability

See full
Gross margin66.9%
Operating margin-16.7%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's preferred stock, par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's preferred stock, par or stated value per share?
BioLife Solutions (BLFS) reported preferred stock, par or stated value per share of $0 in Q1 2026.
How has BioLife Solutions's preferred stock, par or stated value per share changed year-over-year?
BioLife Solutions's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for BioLife Solutions's preferred stock, par or stated value per share?
Over 3 years (2022 to 2025), BioLife Solutions's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.